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QUANTITATIVE MONITORING OF CEFRADINE IN HUMAN URINE 
USING A LUMINOL/SULFOBUTYLETHER–β-CYCLODEXTRIN
CHEMILUMINESCENCE SYSTEM
M. X. Shen,a* X. J. Tan,b Zh. H. Songc UDC 535.379
In this paper, a sensitive, rapid, and simple fl ow-injection chemiluminescence (FI-CL) technique is described for 
determining cefradine in human urine and capsule samples at the picogram level. The results show that cefradine 
within 0.1–100.0 nmol/L quantitatively quenches the CL intensity of the luminol/sulfo butylether–β-cyclodextrin 
(SBE–β-CD) system, with a relative correlation coeffi cient r of 0.9931. Subsequently, the possible mechanism for 
the quenching phenomenon is discussed in detail using the FI-CL and molecular docking methods. The p roposed 
CL method, with a detection limit of 0.03 nmol/L (3σ) and relative standard deviations <3.0% (N = 7), is then 
implemented to monitor the excretion of cefradine in human urine. After orally administration, the cefradine reaches 
a maximum value of 1.37 ± 0.02 mg/mL at 2.0 h in urine, and the total excretion is 4.41 ± 0.03 mg/mL within 8.0 h. 
The absorption rate constant ka, the elimination rate constant ke, and the half-life t1/2 are 0.670 ± 0.008 h−1, 
0.744 ± 0.005 h−1, and 0.93 ± 0.05 h, respectively. 
Keywords: cefradine, sulfobutylether–β-cyclodextrin, luminol, chemiluminescence, fl ow injection technique. 
Introduction. Cefradine (C16H19N3O4S) belongs to the fi rst generation of cephalosporins [1, 2].
aInstitute of Earth Environment, Chinese Academy of Sciences, No . 97 Yanxiang Road, Xi'an 710061, Shaanxi, 
China; email: shenmx@ieecas.cn; bCollege of Earth Sciences and Land Resources, Chang'an University, Xi'an, China; 
cCollege of Chemistry and Materials Science, Northwest University, Xi'an, 710069, China. Published in Zhurnal Prikladnoi 
Spektroskopii, Vol. 85, No. 2, pp. 313–320, March–April, 2018. Original article submitted February 14, 2017.
_____________________
*To whom correspondence should be addressed.
                  0021-9037/18/8502-0327 ©2018 Springer Science+Business Media, LLC 327
Cefradine
This antibiotic agent is widely used against both Gram-positive and Gram-negative microorganisms, inhibiting 
bacterial cell wall synthesis [3, 4]. Several analytical techniques were reporte d for the determination of cefradine in 
pharmaceutical formulations and biological fl uids, including spectrophotometry [5, 6], liquid chromatography-tandem 
mass spectrometry (LC- MS/MS) [7, 8], high-performance liquid chromatography with ultraviolet detection (HPLC-UV) [9], 
capillary zone electrophoresis (CZE) [10], spectrofl uorimetry [11], and colorimetry [12]. Although they have some advantages, 
these reported methods either require expensive equipment or lack analytical sensitivity.
The chemiluminescence (CL) technique, which is characterized by simplicity of operation, simple apparatus, good 
reproducibility, rapid response, high sensitivity, and wide dynamic range, has attracted considerable attention in a wide 
variety of analytical applications [13–16]. The CL method using luminol–copper (II) and luminol–K3Fe (CN)6 systems has 
been applied to cefradine determination in spiked milk samples [17, 18]. To the best of our knowledge, there have been no 
reports on the inhibition phenomenon of cefradine on luminol/sulfobutylether–β-cyclodextrin (SBE–β-CD) CL systems. In 
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the present work, a fl ow injection FI-CL method, based on the quantitative inhibition of cefradine on luminol-SBE–β-CD CL 
systems, is proposed for picogram cefradine determination in human urine samples and cefradine capsules.
The proposed method is also successfully employed to monitor cefradine excretion in human urine. Two hours 
after oral administration, the cefradine level in urine reaches its maximum. The total amount of urine excretion in 8.0 h is 
4.41 ± 0.03 mg/mL. The absorption rate constant ka, the elimination rate constant ke, and the half-life t1/2 are 0.670 ± 0.008 h−1, 
0.744 ± 0.005 h−1, and 0.93 ± 0.05 h, respectively. Recoveries range from 90.0 to 108.5%, and relative standard deviations 
(RSDs) are less than 3.4% (N = 7). 
A possible mechanism for the CL quenching of luminol/SBE–β-CD CL by cefradine is explored by the FI-CL and 
molecular docking methods. Because cefradine is sparingly soluble in water and appears to be released only slowly from 
the site of injection into the plasma [19], the therapeutic application of cefradine is limited. This issue has been addressed 
by complexation of cefradine with a derivative of β-CD [20]. SBE–β-CD is a sulfobutylether derivative of β-CD with an 
average of seven SBE substituents, whic h has an exten ded hydrophobic cavity and an extremely hydrophilic exterior surface 
compared with β-CD [21, 22]. In the fi eld of pharmaceutical research, SBE–β-CD has proved to be capable of forming stable 
inclusion complexes with various poorly water-soluble drugs via noncovalent interactions [23–29]. Analyzed by the FI-CL 
model [30, 33], the formation constant KCD of the SBE–β-CD/cefradine complex is confi rmed in the range 104–105 L/mol 
with a stoichiometric ratio n of 1:1. The thermodynamic parameters (ΔH, ΔS, and ΔG) indicate that the inclusion complex 
formation between cefradine and SBE–β-CD is a spontaneous process proceeding mainly through hydrophobic forces. 
Additionally, the molecular docking studies show that cefradine enters the wider cavity of SBE–β-CD, forming a 1:1 complex 
with hydrogen bonds.
Experimental. The FI-CL apparatus (Xi'an Remax Analysis Instrument Co., Ltd., Xi’an, China), illustrated 
schematically in Fig. 1, included a sampling system, a CL detector, and a recorder. A peristaltic pump was used to propel all 
liquid streams in fl ow lines and a six-way valve, with loops of 100 μL used to inject quantitative luminol to the fl ow cell. The 
CL detector, enclosed in a black box to exclude ambient light, contained a fl ow cell and a photomultiplier tube (PMT). The 
fl ow cell, which was placed close to the PMT, was made by coiling a 15 cm length of colorless glass tube (1.0 mm i.d.) into 
a spiral disk (2.0 cm i.d.). The CL signal produced in the fl ow cell was detected by PMT without wavelength discrimination, 
and the output was recorded by a computer (PC). All of the liquid streams were carried by polytetrafl uoroethylene (PTFE) 
tubing (1.0 mm i.d.).
All reagents used in this work were of analytical reagent grade. Doubly deionized water was prepared using a Milli-Q 
system (Millipore, Bedford, MA, USA). Luminol (Fluka, Biochemika, Switzerland) was purchased from Xi'an Medicine 
Purchasing and Supply Station, Xi'an, China. SBE–β-CD (in which the SBE substituent groups are mainly on the secondary 
rim on C2, C3 of the D-glucopyranose units) was purchased from Zibo Qianhui Fine Chemical Co., Ltd., China. Cefradine 
was purchased from the National Institute for the Control of Pharmaceutical and Biological Products, Beijing, China.
Luminol stock solution (2.5 × 10−2 mol/L) was prepared by dissolving luminol (0.44 g) in NaOH solution 
(0.1 mol/L) in a 100-mL brown calibrated fl ask and stored in the dark. SBE–β-CD stock standard solution (4.0 × 10−4 mol/L) 
was prepared using purifi ed water. A stock solution of cefradine (1.0 × 10−3 mol/L) was prepared using purifi ed water and 
stored at 4oC. Working solutions were prepared daily from the stock solutions by appropriate dilution.
General procedures. As shown in Fig. 1, a peristaltic pump was used to fl ush the whole system with purifi ed water 
at a constant fl ow rate of 2.0 mL/min until a stable baseline was recorded. Luminol (100 μL) was then injected into the fl ow 
line via the valve and merged with the SBE–β-CD solution. Thereafter, the luminol/SBE-β-CD solution was mixed with the 
cefradine solution. The total homogeneous mixed solution was then delivered into the CL cell, and the intensity of the CL 
emission was detected by the PMT, without wavelength discrimination. 
The optimum conditions were found to be: luminol concentration 2.5 × 10−5 mol/L; SBE–β-CD concentration 
1.0 × 10−4 mol/L; NaOH concentration 2.5 × 10−2  mol/L; mixing tube length 10.0 cm; fl ow rate 2.0 mL/min and high voltage 
−750 V. Using these conditions, one analysis cycle, including sampling and washing, could be accomplished in 36 s, offering 
a sampling effi ciency of 100 h−1. The concentration of cefradine could be quantifi ed on the basis of the decrement of CL 
intensity, ∆ICL = I0 – Is, where Is and I0 are the CL intensities in the presence and absence of cefradine, respectively.
Molecular docking. Molecular dock ing was carried out using AutoDock 4.2 software (http://autodock.scripps.
edu/). A model of SBE–β-CD was constructed by replacing seven hydroxyls in the β-CD crystal structure (3M3R) extracted 
from the Protein Data Bank (www.rcsb.org/pdb/). The 3D conformation of cefradine (CID: 38103) was retrieved from the 
National Center for Biotechnology Information (https://www.ncbi.nlm.nih.gov/) and converted to pdb using OpenBabel 2.3.2
(http://openbabel.org/wiki/Main_Page). Docking simulations were performed using a Lamarckian Genetic Algorithm (LGA) to 
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search for the optimum binding energy of SBE–β-CD an d cefradine. The size of the dock ing grid box was 120 × 120 × 120 Å
along the x, y, and z axes (grid box point spacing: 0.375 Å, grid center: –3.560 Å, 27.687 Å, 100.906 Å). The population size 
and the maximum number of evaluations were 150 and 2.5 × 106, respectively. 
Preparation of cefradine capsule samples. Capsules of cefradine (Suzhou Zhonghua Pharmaceutical Co., Ltd., 
Suzhou, China) were weighed and ground to homogenized powder using a pestle and mortar. A sample (equivalent to 
approximately 250 mg of cefradine) was accurately weighed, dissolved in a small amount of deionized water and then diluted 
with deionized water to 100 mL in a calibrated fl ask by ultrasound for 2 min. The solution was fi ltered through general 
purpose fi lter paper, and the fi ltered aliquots were diluted to provide solutions containing cefradine within the calibration 
range.
Results and Discussion. Relative CL intensity–time profi le of different system. The relative CL intensity–time profi les 
of the luminol/dissolved oxygen reaction and the luminol/SBE-β-CD/cefradine reaction are shown in Fig. 2. The times to 
maximum CL intensity Tmax for the luminol/dissolved oxygen reaction (curve 5) and the luminol/SBE-β-CD reaction (curve 1)
are 8.4 and 7.8 s, respectively, and the corresponding maximum CL intensities, Imax, are 194.6 and 555.0, indicating that 
SBE–β-CD can enhance the CL signal of luminol and lead to the complexation enhancement of CL (CEC). The Imax of 
luminol/dissolved oxygen decreases from 194.6 to 190.5 (2.1%), with the same Tmax of 8.4 s, in the presence of cefradine 
(5 nmol/L) (curve 6), suggesting that the interaction between luminol and cefradine is very weak and can be ignored. The 
Imax of the luminol/SBE–β-CD reaction, on the other hand, decreases from 555.0 to 500.8 (9.8%), 442.6 (20.3%) and 384.3 
(30.8%), respectively, with the same Tmax of 7.8 s, in the presence of cefradine (0.5, 5.0, and 50.0 nmol/L) (curves 2–4). The 
decrease in intensity might be attributed to the interaction between SBE–β-CD and cefradine.
Fig. 1. Schematic diagram of the present FI-CL system. (a) Luminol/NaOH; (b) 
deionized water; (c) SBE–β-CD; (d) sample solution. P: pump; M: mixing tube; V: valve; 
FC: fl ow cell; W: Waste; PC: personal computer. Luminol: 2.5 × 10–5 mol/L; NaOH: 
2.5 × 10–2 mol/L; sulfobutylether–β-cyclodextrin: 1.0 × 10–4 mol/L.
Fig. 2. Relative CL intensity/time profi le in systems luminol/SBE–β-CD (1), 
luminol/SBE–β-CD/cefradine (2–4), luminol/O2 (5), and luminol/ce fradine (6); luminol: 
2.5 × 10–5 mol/L; SBE–β-CD: 1.0 × 10–4 mol/L.
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Optimum Conditions for the Determination of Cefradine. The optimum concentrations of luminol solution and 
SBE–β-CD solution for the determination of cefradine, which gave a relatively stable and strong CL intensity, were found to 
be 2.5 × 10−5 and 1.0 × 10−4 mol/L, respectively. For the luminol CL reaction under alkaline conditions, the addition of NaOH 
(2.5 × 10−2 mol/L) provided the most effective enhancement of CL intensity. A fl ow rate of 2.0 mL/min and a 5.0 cm mixing 
tube length gave a good compromise of the signal-noise ratio, sensitivity, precision, reproducibility, sample throughput, and 
reagent consumption.
Stability of the FI-CL system for cefradine determination. Luminol solution (100 μL) was propelled into the fl ow 
system and mixed with SBE–β-CD. The CL intensity was recorded in the presence of cefradine (0.7 and 7.0 nmol/L) to test 
the stability of the luminol/SBE–β-CD system. The experiment lasted for 3 days, and the fl ow system was regularly used 
for over 8 h per day. Seven parallel replicate experiments were conducted, with the resulting average CL intensity and RSDs 
summarized in Table 1. It is clear that the RSDs are lower than 3.4% (N = 7), suggesting that the luminol/SBE–β-CD CL 
system has good stability.
Analytical performance for cefradine determination. Under the optimized experimental conditions, a number of 
cefradine standard solutions were propelled into the fl ow line, with the CL intensity being measured. It is found that cefradine 
strongly quenches the CL intensity of the luminol/SBE–β-CD system, giving decrements of the CL intensity proportional to 
the logarithm of the cefradine concentration over the range 0.1–100 nmol/L. The LOD of this proposed method for cefradine 
determination is 0.03 nmol/L (3σ). The regression equation is ΔI = 25.3 ln C + 71.7 (r= 0.9931), with the RSDs < 3.0 % 
(N = 7).
Interference studies. The interference effect of other components in biological matrices on cefradine quantifi cation 
was tested. With potentially interfering analytes added in cefradine standard solution, the relative CL intensity was examined 
and the corresponding relative error was controlled at the 5% level. The results show that the tolerable concentration ratios 
of the potential matrix components with respect to cefradine (1 nmol/L) are 25 μmol/L (25,000:1) for urea and uric acid, 
2.4 μmol/L (2400:1) for Ca2+, C2O42−, HCO3−, H2PO4−, Zn2+, NO3−, and SO42−, 1.1 μmol/L (1100:1) for NH4+, K+, Na+, Fe2+, 
and Mg2+, and 0.5 μmol/L (500:1) for Cu2+, Co2+, and Mn2+. Other abundant components in human serum and urine, such as 
lipids, proteins, and salts, offer no obvious interference in the determination of cefradine at picomolar levels. 
Possible mechanism of the quenching of luminol/SBE–β-CD CL by cefradine. The possible mechanism for the 
quenching of SBE–β-CD CL by cefradine was studied by the FI-CL and molecular docking methods. The values of KCD 
and n for the SBE–β-CD/cefradine complex at different temperatures are calculated using the FI-CL model, log [(I0 – Is)/Is] 
= log KCD + n log [Ccefradine] [30] (Table 2). By the Van't Hoff equation [31], the values of ΔH, ΔS, and ΔG for the 
SBE–β-CD/cefradine complex are obtained, with the results listed in Table 2. The value of KCD was (1.04 ± 0.02) × 105 L/mol 
at 298 K, suggesting a high affi nity interaction between SBE-β-CD and cefradine. The corresponding value of n was 
0.61, indicating that a 1:1 complex of SBE–β-CD/cefradine had been formed in the fl ow line. The negative sign for ΔG 
demonstrates that the interaction process is spontaneous, and the positive enthalpy change indicates that the formation of 
the SBE–β-CD/cefradine complex is an endothermic interaction. The sign and magnitude of the thermodynamic parameters 
summarized by Ross and Subramanian [32] suggest that the interaction between SBE–β-CD and cefradine is mainly driven 
by the hydrophobic effect.
Molecular docking studies (Fig. 3) reveal that cefradine approaches the wider end of SBE–β-CD and binds to the 
inner surface of the cavity. There are three hydrogen bonds between hydroxyl groups in the α-D-glucopyranose unit of 
SBE–β-CD and hydroxyl groups of cefradine, with bond distances of 1.8, 2.0, and 2.4 Å, respectively. The calculated binding 
energy of SBE–β-CD and cefradine at 298 K was as low as −29.97 kJ/mol, which agrees well with the experimental data. 
Luminol has been reported to enter into the narrow neutral rim of SBE–β-CD forming a 1:1 complex (SBE–β-
CD/lu minol*) [33], which enhances the CL intensity of luminol by complexation enhancement of CL (CEC). A possible 
TABLE 1. Stability Test of the FI-CL System for Cefradine Determination (N = 7)
Time, day ICL(blank) RSD, % ICL(0.7 nmol/L) RSD, % ICL(7.0 nmol/L) RSD, %
1st 555 1.2 492 2.6 434 1.8
2nd 553 1.5 496 2.4 431 2.0
3rd 558 1.0 489 3.0 437 1.7
331
mechanism for the CL quenching in the luminol/SBE–β-CD/cefradine system could be described as follows. Luminol enters 
into the narrow neutral rim of SBE–β-CD, leading to an enhanced CL intensity of luminol by CEC, while cefradine enters 
into the wide rim and forms a complex by hydrophobic interactions, resulting in strong quenching of the CL intensity of 
SBE–β-CD/luminol by complexation enhancement of quenching (CEQ) (Fig. 2). The KL-CD of luminol/SBE–β-CD has been 
reported as 3.3 × 106 L/mol, which is close to the KCD (1.04 × 105 L/mol). From the discussion above, it is obvious that 
luminol enters into the narrow neutral rim and cefradine enters into the wide rim of SBE–β-CD, showing that there is no 
competitive effect between luminol and cefradine in terms of interacting with SB–β-CD.
Applications of the Proposed Method. Determination of cefradine in capsules. Cefradine capsules were weighed 
and ground to a fi ne powder. A sample equivalent to approximately ten capsules was accurately weighed and dissolved in 
purifi ed water. By using the spiked-recovery method, the resulting solution was fi ltered through general purpose fi lter paper 
Fig. 3. Docking result of the sulfobutylether–β-cyclodextrin/cefradine.
TABLE 2. Formation Constants and Thermodynamic Parameters of SBE–β-CD/cefradine
T, K KCD, L/mol n ΔH, kJ/mol ΔS, J × mol−1 × K−1 ΔG, kJ/mol
288 (8.01 ± 0.03) × 104 0.60
24.51 ± 0.02 178.76 ± 0.02
−26.97 ± 0.03
298 (1.04 ± 0.02) × 105 0.61 −28.76 ± 0.02
308 (1.56 ± 0.02) × 105 0.62 −30.55 ± 0.02
TABLE 3. Results of the Determination of Cefradine in Capsules (N = 7)
Sample No. Added/Found, ng/mL RSD, % Recovery, % Content of cefradine,
*
g/per capsule
1
0/4.96 2.8
93.0 0.248 ± 0.006/0.250
3.0/7.75 1.6
2
0/5.05 1.8
105.4 0.252 ± 0.004/0.250
5.0/10.32 1.3
3
0/4.98 2.5
95.4 0.249 ± 0.006/0.250
7.0/11.66 1.0
4
0/5.01 1.9
102.5 0.251 ± 0.005/0.250
10.0/15.26 0.6
*Declared content: 250.0 mg per capsule.
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and diluted to 100 mL in a calibrated glass fl ask. The samples were directly determined using the proposed CL method, with 
the results given in Table 3. Obviously, the determination recoveries for cefradine are 93.0–105.4%, and RSDs are less than 
2.8% (N = 7), showing that this proposed method is capable of quantifying cefradine in capsule samples.
In vitro monitoring of cefradine excreted in human urine after taking cefradine capsules. Two cefradine capsules 
(labeled 250 mg cefradine per capsule) were administered orally to a healthy volunteer in the morning on an empty stomach. 
Urine samples of 0.5 mL were periodically collected in polypropylene tubes (1.0 mL) during 8 h. The urine samples were 
then treated ultrasonically for 3 min and centrifuged at 8000 rpm for 5 min. Then 0.1 mL of aliquot from the supernatant 
was transferred and appropriately diluted by purifi ed water. Then the dilution was directly determined using the proposed 
CL method. A urine sample taken before administration of the capsules was treated as described above and used as the 
blank sample. Recoveries were in the range 90.0–108.5% (Table 4). The concentration–time curve for cefradine in human 
urine is presented in Fig. 4. The cefradine concentration reached a maximum value Cmax = 1.37 ± 0.02 mg/mL at 2 h after 
oral administration. The absorption rate constant ka, elimination rate constant ke, and half-life time t1/2 of cefradine were 
0.670 ± 0.008 h–1, 0.744 ± 0.005 h–1, and 0.93 ± 0.05 h, respectively.
Fig. 4. Concentration vs. time curve of monitoring cefradine in human urine.
TABLE 4. Continuous Monitoring of the Excretion of Cefradine in Human Urine within 8 h (N = 7)
Time, h Added, ng/mL Found, ng/mL Recovery, % RSD, % Cefradine in urine, mg/mL
0.5
0 10.8
108.5
2.2
0.54 ± 0.02
7.0 18.4 1.9
1.0
0 19.6
93.0
1.3
0.98 ± 0.02
10.0 28.9 1.1
2.0
0 27.4
91.4
1.2
1.37 ± 0.02
7.0 33.8 0.7
3.0
0 12.2
108.0
2.0
0.61 ± 0.03
5.0 17.6 1.6
4.0
0 8.8
106.7
2.4
0.44 ± 0.03
3.0 12.0 2.1
5.0
0 4.6
90.0
2.7
0.23 ± 0.02
2.0 6.4 2.5
6.0
0 3.2
105.0
2.9
0.16 ± 0.03
2.0 5.3 2.8
7.0
0 1.5
90.0
3.3
0.08 ± 0.03
1.0 2.4 3.0
8.0
0 –
–
–
–/80
1.0 0.9 3.4
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Conclusions. We have successfully developed an FI-CL analytical approach for the determination of cefradine 
at picomolar levels with simplicity of operation, high sample output, and good reproducibility. A comparison between the 
proposed CL method and other reported methods for cefradine determination in different matrices is provided in Table 5. 
It is clear that this proposed FI-CL analysis is attractive in terms of wide linear range and relatively high sensitivity. The 
satisfactory results obtained for the determination of cefradine in biological fl uids confi rm the prospects of the proposed CL 
method for further application in pharmacological and clinical research.
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